UK failing to capitalise on graphene


A new policy statement from the Institution of Mechanical Engineers (IMechE) warns that while UK universities lead the world in graphene development, the country’s poor commercialisation of the material could see it fall behind.

Graphene is a flat sheet of carbon atoms, a single atomic layer arranged in a hexagonal arrangement reminiscent of chicken wire. Andre Geim and Kostya Novoselov at the University of Manchester first produced the material in 2004, and received the 2010 Nobel prize for physics for their discovery.

Scientists have since discovered graphene has a number of impressive optical, electronic and mechanical properties that could lead to numerous new applications. However, IMechE has found that while over 7500 graphene-based patents had been filed worldwide, only 54 are from the UK. In comparison, over 2200 are from China and 1754 from South Korea – Korea’s Samsung alone holds 407 patents. The institute warns that UK government and industry must work collaboratively with academia to develop a coherent strategy if the country is to reap the benefits of graphene.


Related Content

Forensic science service closure criticised

30 July 2013 News and Analysis

news image

UK science and technology committee warns that crimes may go unsolved thanks to underfunding and outdated technology

Nanotech patent jungle set to become denser in 2013

17 January 2013 News and Analysis

news image

Is a thicket of patents strangling a nascent industry?

Most Read

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

The mothers of invention

24 February 2015 Managing Change

news image

Nina Notman profiles four researchers successfully balancing an academic career with family life

Most Commented

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

Hepatitis C drug patent challenged in Europe

19 February 2015 Business

news image

Campaign group says Gilead’s expensive blockbuster sofosbuvir is not innovative enough to warrant a patent